Welcome to our dedicated page for SEELOS THERAPEUTICS news (Ticker: SEEL), a resource for investors and traders seeking the latest updates and insights on SEELOS THERAPEUTICS stock.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a clinical-stage biopharmaceutical company committed to developing and commercializing novel therapeutic solutions for central nervous system (CNS) disorders and rare ailments. Based in New York, the company's primary focus is on innovative technologies aimed at treating conditions like major depressive disorder (MDD), post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), and more.
Key developments in Seelos' pipeline include:
- SLS-002: An intranasal racemic ketamine targeting acute suicidal ideation and behavior in MDD and PTSD patients. This promising treatment has shown significant efficacy in Phase II trials, with plans for Phase III trials underway.
- SLS-005: A protein stabilizer for treating Sanfilippo syndrome and ALS. Recent trials in collaboration with the HEALEY ALS Platform have highlighted its potential benefits, even though some endpoints were not statistically significant.
- SLS-006: A partial dopamine agonist developed for PD patients, emphasizing symptom relief and improved quality of life.
- Preclinical Programs: These include SLS-007, an anti-alpha-synuclein inhibitor for PD; SLS-008, targeting chronic inflammation in asthma and pediatric orphan indications; and SLS-004 and SLS-010 for PD and narcolepsy, respectively.
Seelos Therapeutics actively engages in various clinical trials and collaborations to advance its therapeutic offerings. The company recently announced public offerings and strategic financial maneuvers to support its robust pipeline, including offerings totaling approximately $10.65 million in gross proceeds. These funds are earmarked for advancing Seelos' clinical programs and general corporate purposes.
Committed to addressing unmet medical needs, Seelos Therapeutics is poised to make significant contributions to the biopharmaceutical landscape, with a keen focus on CNS disorders and rare diseases.
Seelos Therapeutics (Nasdaq: SEEL) announced positive data from its Proof-of-Concept study of SLS-002, indicating significant efficacy and safety in treating Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD). The study showed a 76.5% response rate on Day 1 and 100% on Day 29. SLS-002 was well tolerated, with no serious adverse events reported. With the need for effective treatments for suicidality exacerbated by the COVID-19 pandemic, SLS-002 presents a promising new option for patients. A double-blind Part 2 study is forthcoming.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the 2021 Jefferies Virtual Healthcare Conference from June 1-4, 2021. The company's Chairman and CEO, Raj Mehra, Ph.D., is scheduled to present on June 3rd at 10:30am ET and will also hold 1x1 meetings. Seelos focuses on developing novel therapeutics for central nervous system disorders and rare diseases, with key assets targeting serious conditions such as Major Depressive Disorder and Amyotrophic Lateral Sclerosis. Registration for the presentation can be found here.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has received a positive opinion for European Orphan Drug Designation for SLS-005 in treating amyotrophic lateral sclerosis (ALS) from the European Medicines Agency (EMA). The European Commission is expected to grant this designation within 30 days, which will provide Seelos with benefits like protocol assistance and market exclusivity. SLS-005 has also received Orphan Drug Designation from the FDA for ALS and other conditions, along with Fast Track designation for Oculopharyngeal Muscular Dystrophy (OPMD).
Seelos Therapeutics, Inc. (Nasdaq: SEEL) will participate in the 2021 RBC Capital Markets Global Healthcare Conference from May 18-20, 2021. Chairman and CEO Raj Mehra, Ph.D., is set to present on May 18 at 4:50 PM ET and will host 1x1 meetings on May 18 and 19. The company is dedicated to developing therapies for central nervous system disorders and rare diseases, with a portfolio targeting conditions like Major Depressive Disorder, amyotrophic lateral sclerosis (ALS), and Sanfilippo syndrome. For further details, visit their website.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced its participation in the B. Riley Securities' Neuroscience Conference on April 28-29, 2021. Chairman and CEO Raj Mehra, Ph.D., will present on April 28 at 11:00am ET. The conference will address critical topics in neurodegeneration, neuropsychiatry, and mental health, featuring various healthcare companies. Seelos focuses on developing therapies for CNS disorders and rare diseases, boasting a portfolio that includes clinical assets for Acute Suicidal Ideation and Behavior (ASIB), ALS, and Parkinson's disease.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has signed a Strategic Device Partnership with AptarGroup, Inc. (NYSE: ATR) for the co-exclusive use of Aptar Pharma's Bidose Liquid System to enhance the delivery of its intranasal ketamine candidate, SLS-002. This device is pivotal for treating suicidality, depression, and PTSD. Seelos has successfully completed part 1 of its Proof-of-Concept study involving 16 patients, and expects to share key data in Q2 2021. This partnership aims to optimize the franchise for SLS-002, addressing an urgent need for effective treatments in critical situations.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) has completed patient enrollment for Part 1 of its Proof of Concept study of SLS-002 (intranasal ketamine) aimed at treating Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder. Results from Part 1, involving 16 participants, are anticipated in Q2 2021, following the last patient's completion on April 1, 2021. The company plans to expand the trial in Part 2, enrolling around 120 patients. This study addresses the significant unmet need in rapid depression treatment.
Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced an amendment to its agreement with Vyera Pharmaceuticals AG to repurchase a significant portion of the royalties from future sales of SLS-002, an intranasal ketamine therapy. This move reduces royalty obligations from mid-teens to a mid-single digit percentage, aimed at enhancing shareholder value. SLS-002 is currently being studied to treat major depressive disorder in patients at imminent risk of suicide. The company is optimistic about the clinical development and potential commercialization of this therapy.
Seelos Therapeutics (Nasdaq: SEEL) will participate in the 33rd Annual Roth Conference virtually from March 15-17, 2021. Chairman and CEO Raj Mehra, Ph.D., will conduct 1x1 meetings on March 16 and 17. The company focuses on developing therapies for central nervous system disorders and rare diseases, with a portfolio including treatments for conditions like Acute Suicidal Ideation in Major Depressive Disorder and Parkinson's disease. For more information, visit seelostherapeutics.com.
Seelos Therapeutics (Nasdaq: SEEL) announced the issuance of a new patent from the Australian Patent Office for its drug SLS-005, aimed at treating neurodegenerative diseases linked to protein aggregation. The patent covers a method of intravenous administration of trehalose to address conditions such as oculopharyngeal muscular dystrophy and spinocerebellar ataxia. Trehalose helps stabilize proteins and activates autophagy, potentially reducing the impact of misfolded proteins in cells, as demonstrated in animal studies.
FAQ
What is the current stock price of SEELOS THERAPEUTICS (SEEL)?
What is the market cap of SEELOS THERAPEUTICS (SEEL)?
What does Seelos Therapeutics, Inc. do?
What are the key products in Seelos Therapeutics' pipeline?
What recent achievements has Seelos Therapeutics made?
How does SLS-002 work?
What is the financial status of Seelos Therapeutics?
Who are Seelos Therapeutics' key partners?
What is SLS-005, and what does it treat?
What is the status of SLS-005 in clinical trials?
How is Seelos Therapeutics funded?
What are the future plans for Seelos Therapeutics?
